Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The diagnosis of nonalcoholic fatty liver disease and associated fibrosis is challenging given the lack of signs, symptoms and nonexistent diagnostic test. Furthermore, follow up and treatment decisions become complicated with a lack of a simple reproducible method to follow these patients longitudinally. Liver biopsy is the current standard to detect, risk stratify and monitor individuals with nonalcoholic fatty liver disease. However, this method is an unrealistic option in a population that affects about one in three to four individuals worldwide. There is an urgency to develop innovative methods to facilitate management at key points in an individual’s journey with nonalcoholic fatty liver disease fibrosis. Artificial intelligence is an exciting field that has the potential to achieve this. In this review, we highlight applications of artificial intelligence by leveraging our current knowledge of nonalcoholic fatty liver disease to diagnose and risk stratify NASH phenotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Forlano, R., Mullish, B. H., Giannakeas, N., Maurice, J. B., Angkathunyakul, N., Lloyd, J., Tzallas, A. T., Tsipouras, M., Yee, M., Thursz, M. R., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.12.025 · Cited by 142
Atabaki-Pasdar, N., Ohlsson, M., Viñuela, A., Frau, F., Pomares-Millan, H., Haid, M., Jones, A. G., Thomas, E. L., Koivula, R. W., Kurbasic, A., et al. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003149 · Cited by 97 · cited 2×
“Further studies to differentiate NAFLD stages are included in Table 1.(5,6)”
Background
Cited by
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Self-citationChang, D., Truong, E., Mena, E. A., Pacheco, F., Wong, M., Guindi, M., Todo, T. T., Noureddin, N., Ayoub, W., Yang, J. D., et al. (2023) · Hepatology · doi:10.1002/hep.32655 · Cited by 92
“30] In this paper, we developed ML models to predict fibrosis stages and identify patients at risk of NASH and significant fibrosis, as well as cirrhosis, in patients with NAFLD.”
MethodSelf-citationQadri, S., Vartiainen, E., Lahelma, M., Porthan, K., Tang, A., Idilman, I. S., Runge, J. H., Juuti, A., Penttilä, A. K., Dabek, J., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2023.100928 · Cited by 55
Metadata
- Authors
- Dinani, A. M., Kowdley, K. V., & Noureddin, M.
- Venue
- Hepatology
- Published
- 2021-08-10
- Volume
- 74
- Issue
- 4
- Pages
- 2233-2240
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3157759000
- Cited by
- 43
- References
- 2
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.